Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy

The purpose of this study is to determine whether it is feasible to administer high-dose epirubicin (135 mg m(−2)) combined with a fixed dose of cisplatin every 2 weeks with G-CSF support in patients with metastatic non-small-cell lung cancer (NSCLC). Subsequently, the efficacy of the recommended do...

Descripción completa

Detalles Bibliográficos
Autores principales: Huisman, C, Biesma, B, Postmus, P E, Giaccone, G, Schramel, F M N H, Smit, E F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363962/
https://www.ncbi.nlm.nih.gov/pubmed/11720428
http://dx.doi.org/10.1054/bjoc.2001.2013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363962/
https://www.ncbi.nlm.nih.gov/pubmed/11720428
http://dx.doi.org/10.1054/bjoc.2001.2013

Ejemplares similares